Background: It has been proposed that bacterial lysates may serve as a suitable immunomodulatory oral medication to improve and control asthma symptoms. However, the difference in its efficacy in adults and children remains unclear.
Methods: Randomized controlled trials (RCTs) evaluating OM-85 add-on therapy in asthma patients up to December 2021 were searched using PubMed, Scopus, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang database, and WP (WeiPu) database. Risk of bias was evaluated using the Cochrane risk of bias assessment tool.
Results: A total of 36 studies were included. The results showed that OM-85 add-on treatment provided a 24% improvement in asthma symptom control [relative rates (RR) =1.24, 95% confidence intervals (CI): 1.19-1.30], and also significantly improved lung function, increased numbers of T-lymphocytes and the subtypes, and elevated levels of interferon-γ (IFN-γ), interleukin-10 (IL-10), and IL-12. Levels of serum immunoglobulin E (IgE), eosinophil cationic protein (ECP) and pro-inflammatory cytokines (including IL-4 and IL-5) were suppressed in the OM-85 add-on treatment group. Moreover, OM-85 add-on treatment showed more prominent effects in asthmatic children than in asthmatic adults.
Conclusions: OM-85 add-on therapy showed important clinical benefits for patients with asthma, especially asthmatic children. Further studies focusing on the immunomodulatory function of OM-85 in personalized asthma treatment are warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323573 | PMC |
| http://dx.doi.org/10.21037/jtd-22-1469 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer.
J Immunol Res
July 2024
School of Pharmacy and Medical Sciences Griffith University, Gold Coast 4222, QLD, Australia.
Article Synopsis
- Bacterial lysates contain immunostimulants that can boost both local and systemic immune responses, aiding in the treatment of infectious diseases and potentially cancer.
- The review discusses various commercially available bacterial lysates, such as OM-85 and OM-89, showing effectiveness in managing respiratory and urinary tract infections with minimal side effects.
- Additionally, bacterial lysates may enhance innate immunity for cancer treatment, with research suggesting their potential as adjuvants in therapies for different types of cancer, including bladder cancer and sarcomas.
Bacterial lysate add-on therapy in adult and childhood asthma: a systematic review and meta-analysis.
J Thorac Dis
June 2023
Department of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Background: It has been proposed that bacterial lysates may serve as a suitable immunomodulatory oral medication to improve and control asthma symptoms. However, the difference in its efficacy in adults and children remains unclear.
Methods: Randomized controlled trials (RCTs) evaluating OM-85 add-on therapy in asthma patients up to December 2021 were searched using PubMed, Scopus, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang database, and WP (WeiPu) database.
OM-85 Broncho-Vaxom, a Bacterial Lysate, Reduces SARS-CoV-2 Binding Proteins on Human Bronchial Epithelial Cells.
Biomedicines
October 2021
Pulmonary Cell Research, Department of Biomedicine & Internal Medicine, University Hospital Basel, CH-4031 Basel, Switzerland.
In clinical studies, OM-85 Broncho-Vaxom, a bacterial lysate, reduced viral respiratory tract infection. Infection of epithelial cells by SARS-CoV-2 depends on the interaction of its spike-protein (S-protein) with host cell membrane proteins. In this study, we investigated the effect of OM-85 on the expression of S-protein binding proteins by human bronchial epithelial cells.
View Article and Find Full Text PDFBacterial lysate add-on therapy to reduce exacerbations in severe asthma: A double-blind placebo-controlled trial.
Clin Exp Allergy
September 2021
Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Article Synopsis
- Asthma attacks in adults can be triggered by respiratory infections, and there's interest in using bacterial lysates to help manage these attacks.
- A study was conducted with 75 adults with severe asthma, where they received either a bacterial lysate (OM-85) or a placebo over six months to see if it would reduce asthma exacerbations and improve lung function.
- Results showed no significant difference in asthma attack frequency between the two groups after 18 months, but there was an improvement in lung function and a lower detection rate of viruses during infections in the OM-85 group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!